These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 20534644

  • 1. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
    Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B.
    Mult Scler; 2010 Aug; 16(8):964-9. PubMed ID: 20534644
    [Abstract] [Full Text] [Related]

  • 2. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.
    Cree BA, Kornyeyeva E, Goodin DS.
    Ann Neurol; 2010 Aug; 68(2):145-50. PubMed ID: 20695007
    [Abstract] [Full Text] [Related]

  • 3. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, Kappos L.
    Mult Scler; 2011 Nov; 17(11):1341-50. PubMed ID: 21727148
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL, Wynn DR, Alam MS, Valdes J.
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [Abstract] [Full Text] [Related]

  • 6. Quality of life in multiple sclerosis: should clinicians trust proxy ratings?
    Tripoliti E, Campbell C, Pring T, Taylor-Goh S.
    Mult Scler; 2007 Nov; 13(9):1190-4. PubMed ID: 17623731
    [Abstract] [Full Text] [Related]

  • 7. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 8. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T, Heersema DJ, Mostert JP, Heerings M, Admiraal-Behloul F, Talebian A, van Buchem MA, De Keyser J.
    Neurology; 2005 Dec 13; 65(11):1764-8. PubMed ID: 16221950
    [Abstract] [Full Text] [Related]

  • 9. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
    Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.
    Mult Scler; 2008 Sep 13; 14(8):1076-83. PubMed ID: 18728058
    [Abstract] [Full Text] [Related]

  • 10. Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis.
    Montel SR, Bungener C.
    Mult Scler; 2007 Apr 13; 13(3):393-401. PubMed ID: 17439909
    [Abstract] [Full Text] [Related]

  • 11. Family caregiver quality of life in multiple sclerosis among Kuwaitis: a controlled study.
    Alshubaili AF, Ohaeri JU, Awadalla AW, Mabrouk AA.
    BMC Health Serv Res; 2008 Oct 07; 8():206. PubMed ID: 18840287
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
    Malekzad F, Arbabi M, Mohtasham N, Toosi P, Jaberian M, Mohajer M, Mohammadi MR, Roodsari MR, Nasiri S.
    J Eur Acad Dermatol Venereol; 2009 Aug 07; 23(8):948-50. PubMed ID: 19453814
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effect of two types of acupuncture on quality of life in secondary progressive multiple sclerosis: a preliminary single-blind randomized controlled trial.
    Donnellan CP, Shanley J.
    Clin Rehabil; 2008 Mar 07; 22(3):195-205. PubMed ID: 18285429
    [Abstract] [Full Text] [Related]

  • 15. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
    Idiman E, Uzunel F, Ozakbas S, Yozbatiran N, Oguz M, Callioglu B, Gokce N, Bahar Z.
    J Neurol Sci; 2006 Jan 15; 240(1-2):77-80. PubMed ID: 16277993
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
    Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M.
    Neurol Res; 2016 Oct 15; 38(10):888-92. PubMed ID: 27597724
    [Abstract] [Full Text] [Related]

  • 18. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL, Stammer H, Jost G, Rufli T, Büchner S, Bigliardi-Qi M.
    J Am Acad Dermatol; 2007 Jun 15; 56(6):979-88. PubMed ID: 17320241
    [Abstract] [Full Text] [Related]

  • 19. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K, Pelicon K, Ledinek AH, Sega S.
    Clin Neurol Neurosurg; 2015 Dec 15; 139():35-40. PubMed ID: 26363365
    [Abstract] [Full Text] [Related]

  • 20. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group.
    Neurology; 2008 Jul 22; 71(4):265-71. PubMed ID: 18645164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.